Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+1-510-4563805
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees31
OptionableOptionable
Asterias Biotherapeutics (NYSEAMERICAN:AST) Frequently Asked Questions
What is Asterias Biotherapeutics' stock symbol?
Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AST."
How were Asterias Biotherapeutics' earnings last quarter?
Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) announced its quarterly earnings data on Tuesday, March, 28th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.01. The biotechnology company earned $1.75 million during the quarter, compared to analysts' expectations of $2.81 million. View Asterias Biotherapeutics' Earnings History.
When is Asterias Biotherapeutics' next earnings date?
What price target have analysts set for AST?
3 brokers have issued 12-month target prices for Asterias Biotherapeutics' shares. Their forecasts range from $6.00 to $11.00. On average, they expect Asterias Biotherapeutics' stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 855.1% from the stock's current price. View Analyst Price Targets for Asterias Biotherapeutics.
What is the consensus analysts' recommendation for Asterias Biotherapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Asterias Biotherapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Asterias Biotherapeutics.
What are Wall Street analysts saying about Asterias Biotherapeutics stock?
Here are some recent quotes from research analysts about Asterias Biotherapeutics stock:
- 1. According to Zacks Investment Research, "Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company's technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. " (2/14/2019)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We use a sum-of- the-parts approach, which ascribes a $440M risk-adjusted net present value (rNPV) to the AST-OPC1 program in AST-VAC programs in NSCLC and prostate cancer." (9/5/2018)
Has Asterias Biotherapeutics been receiving favorable news coverage?
News coverage about AST stock has trended positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Asterias Biotherapeutics earned a daily sentiment score of 2.3 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the near term.
Are investors shorting Asterias Biotherapeutics?
Asterias Biotherapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 430,397 shares, an increase of 19.2% from the January 15th total of 361,141 shares. Based on an average daily trading volume, of 288,497 shares, the days-to-cover ratio is presently 1.5 days. Currently, 1.3% of the shares of the company are short sold. View Asterias Biotherapeutics' Current Options Chain.
Who are some of Asterias Biotherapeutics' key competitors?
Some companies that are related to Asterias Biotherapeutics include Fennec Pharmaceuticals (FRX), BELLUS Health (BLU), CorMedix (CRMD), CorMedix (CRMD), Cynata Therapeutics (CYP), BioTime (BTX), BioTime (BTX), Aerpio Pharmaceuticals (ARPO), Neuren Pharmaceuticals (NEU), Pfenex (PFNX), Matinas Biopharma (MTNB), Matinas BioPharma (MTNB), Equillium (EQ), Covalon Technologies (COV) and Immutep (IMM).
Who are Asterias Biotherapeutics' key executives?
Asterias Biotherapeutics' management team includes the folowing people:
- Mr. Michael H. Mulroy, Chief Exec. Officer, Pres & Director (Age 53)
- Dr. Edward D. Wirth III, Chief Medical Officer (Age 54)
- Dr. Katharine E. Spink, Consultant (Age 45)
- Mr. Stephen L. Cartt, Advisor & Director (Age 56)
- Mr. Ryan D. Chavez, CFO & Gen. Counsel (Age 43)
Who are Asterias Biotherapeutics' major shareholders?
Which institutional investors are selling Asterias Biotherapeutics stock?
Which institutional investors are buying Asterias Biotherapeutics stock?
How do I buy shares of Asterias Biotherapeutics?
Shares of AST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Asterias Biotherapeutics' stock price today?
One share of AST stock can currently be purchased for approximately $0.89.
How big of a company is Asterias Biotherapeutics?
Asterias Biotherapeutics has a market capitalization of $49.54 million. Asterias Biotherapeutics employs 31 workers across the globe.
What is Asterias Biotherapeutics' official website?
How can I contact Asterias Biotherapeutics?
Asterias Biotherapeutics' mailing address is 6300 Dumbarton Cir, FREMONT, CA 94555-3644, United States. The biotechnology company can be reached via phone at +1-510-4563805.
MarketBeat Community Rating for Asterias Biotherapeutics (NYSEAMERICAN AST)
MarketBeat's community ratings are surveys of what our community members think about Asterias Biotherapeutics and other stocks. Vote "Outperform" if you believe AST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AST will underperform the S&P 500 over the long term. You may vote once every thirty days.
